Killing AML Cells with Magrolimab, a New Immunotherapy Option, with Dr. Joseph Jurcic
IF YOU WOULD PREFER TO JOIN THE SHOW BY PHONE, PLEASE CALL (515) 602-9728
*you need to join by phone if you want to ask Dr. Jurcic your questions.
Immunotherapy is one of the most promising areas of cancer research. Drugs like checkpoint inhibitors, monoclonal and bispecific anitbodies, antibody drug conjugates and CAR-T cell therapy are all extensively being studied in AML.
Join us live on May 26th at 11 AM EST to learn from Dr. Joseph Jurcic, an AML expert from the Herbert Irving Comprehensive Cancer Center at Columbia University, about an exciting new immunotherapy drug in development called magrolimab which is a monoclonal antibody against CD47 and macrophage checkpoint inhibitor.
During the show, Dr. Jurcic will discuss what magrolimab is, how it is helping AML patients and two upcoming trials he will be participating in that will use magrolimab in combination with other AML drugs. Learn all about the immune system and this emerging therapy with a unique opportunity to directly ask Dr. Jurcic your questions!
Joseph Jurcic, MD
Attending Physician in the Deparment of Medicine at New York-Presbyterian/Columbia University Medical Center, Professor of Medicine at Columbia University Irving Medical Center and Director of the Hematologic Malignancies Section in the Division of Hematology/Oncology.
Kerith Amen
Kerith joined HealthTree Foundation as a Community Co-Director for AML in 2022. She is a mother to a spirited eight-year-old daughter, Adair, and their beloved rescue, Violet. She lost her best friend and husband, Rob, to AML in March 2018. Kerith wishes she had a resource such as HealthTree for AML during Rob’s illness. She is a strong supporter of HealthTree's mission. She hopes that by sharing her experience, she may help other patients and caregivers navigate an AML diagnosis.